Positive new cardiovascular death risk data with diabetes drug Jardiance

New data showed that Jardiance (empagliflozin) reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.

These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of German family-owned pharma major Boehringer Ingelheim and its partner Eli Lilly (NYSE: LLY) at the American Heart Association (AHA) Scientific Sessions 2017 in Anaheim, California and simultaneously published online in the AHA’s journal Circulation.1

“Peripheral artery disease, one of the most common cardiovascular complications associated with type 2 diabetes, increases the risk of death from cardiovascular causes,” said Dr Subodh Verma, cardiac surgeon-scientist at St Michael’s Hospital and professor at the University of Toronto, Canada. “There is an urgent need for treatment options that can improve cardiovascular-related outcomes in people with type 2 diabetes and peripheral artery disease.”